Nanobiotix achieves milestone in cancer treatment with NBTXR3, secures $20m from Janssen
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX), a leader in the field of biotechnology, announced a significant achievement in its ongoing pivotal Phase 3 study, NANORAY-312. The study, which is evaluating the potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, has met operational requirements, resulting in a $20 million milestone payment from […]